Capricor Therapeutics ( (CAPR) ) has issued an update.
On March 4, 2025, Capricor Therapeutics announced that the FDA has accepted its Biologics License Application for deramiocel, an investigational cell therapy for Duchenne muscular dystrophy cardiomyopathy, and granted it Priority Review with a target action date of August 31, 2025. If approved, deramiocel would be the first therapy for this condition, potentially offering a new treatment landscape for patients and stakeholders in the DMD community.
More about Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company focused on developing transformative cell and exosome-based therapeutics for rare diseases. Their lead product candidate, deramiocel, is an allogeneic cardiac-derived cell therapy aimed at treating dystrophinopathies and heart disease, currently in late-stage development for Duchenne muscular dystrophy. Capricor is also advancing its exosome technology for potential treatments in various medical areas.
YTD Price Performance: 2.81%
Average Trading Volume: 1,146,418
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $699.3M
For detailed information about CAPR stock, go to TipRanks’ Stock Analysis page.